Global Dialysis Induced Anemia Treatment Market Size to Exceed USD 3.86 Billion By 2035 | CAGR of 7.24%
Category: HealthcareGlobal Dialysis Induced Anemia Treatment Market Size to Exceed USD 3.86 Billion By 2035
According To A Research Report Published By Spherical Insights & Consulting, The Global Dialysis Induced Anemia Treatment Market Size Is Expected To Grow From USD 1.87 Billion In 2024 To USD 3.86 Billion By 2035, At A CAGR Of 7.24% During The Forecast Period 2025-2035.
Get more details on this report -
Browse key industry insights spread across 210 pages with 107 Market data tables and figures & charts from the report on the "Global Dialysis Induced Anemia Treatment Market Size, Share, and COVID-19 Impact Analysis, By Treatment (Erythropoiesis-stimulating Agents, Iron Supplements, HIF-PH Inhibitors, and Combination Therapies), By Sales Channel (Hospital Pharmacies, Dialysis Centers, Retail Pharmacy Chains, and Mail Order Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/dialysis-induced-anemia-treatment-market
The dialysis induced anemia treatment market includes the worldwide industry devoted to developing, manufacturing, and distributing treatment solutions for anemia caused by dialysis in patients with chronic kidney disease (CKD). Improving hemoglobin management, reducing the need for blood transfusions, and creating therapies like ESAs and HIF-PHIs to enhance the prognosis of dialysis patients with chronic renal illness are the main goals of the market for dialysis-induced anemia treatment. These factors, which are also promoting innovation and expanding the therapeutic reach, are driving the market for the treatment of dialysis-induced anemia. Dialysis-induced anemia is increasingly being treated with intravenous iron supplements, such as ferric carboxymaltose and iron sucrose. The market for dialysis-induced anemia treatment is being driven by a number of significant reasons, including rising prevalence of chronic kidney disease, advances in injectable iron therapy, increasing dialysis techniques, and the growing use of biosimilars and erythropoiesis-stimulating medications. However, high treatment costs, negative drug side effects, restricted access in low-income areas, and delays in regulatory approval are some of the restraining factors market.
The iron supplements segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the treatment, the dialysis induced anemia treatment market is divided into erythropoiesis-stimulating agents, iron supplements, HIF-PH inhibitors, and combination therapies. Among these, the iron supplements segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. Iron supplements are essential for dialysis patients, especially those with chronic kidney disease (CKD), in order to support erythropoiesis and restore iron levels.
The hospital pharmacies segment accounted for a largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the sales channel, the dialysis induced anemia treatment market is divided into hospital pharmacies, dialysis centers, retail pharmacy chains, and mail order pharmacies. Among these, the hospital pharmacies segment accounted for a largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. The administration of erythropoiesis-stimulating agents (ESAs) and iron treatments in inpatient and dialysis settings is a critical function of hospital pharmacists.
North America is expected to hold the majority share of the global dialysis induced anemia treatment market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global dialysis induced anemia treatment market during the forecast period. Medicare bundle payments have maintained coverage for intravenous iron and erythropoiesis-stimulating agents (ESAs), promoting dose that is in line with guidelines. The FDA's Fast-Track and Breakthrough programs have expedited evaluations of hypoxia-inducible-factor (HIF) stabilizers, increasing the range of available treatments.
Asia Pacific is anticipated to grow at the fastest pace in the global dialysis induced anemia treatment market during the forecast period. In order to improve early detection of low hemoglobin, the Healthy China 2030 blueprint required anemia screening in National Basic Public Health Services. India is growing more rapidly thanks to advancements in healthcare, an expanding patient base, and easier access to dialysis.
Major vendors in the global dialysis induced anemia treatment market are Novartis, Amgen, GSK plc, Biocon, Roche, CSL Vifor, Akebia Therapeutics, Teva Pharmaceuticals, Johnson & Johnson (J&J), and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In February 2023, the oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), Jesduvroq has been approved by the US Food and Drug Administration (FDA) to treat anemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for at least four months. This approval was made public by GSK today. As the only HIF-PHI authorized in the United States and the first novel medication for treating anemia in more than three decades, Jesduvroq offers patients with CKD anemia receiving dialysis a new, practical oral option.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the dialysis induced anemia treatment market based on the below-mentioned segments:
Global Dialysis Induced Anemia Treatment Market, By Treatment
- Erythropoiesis-stimulating Agents
- Iron Supplements
- HIF-PH Inhibitors
- Combination Therapies
Global Dialysis Induced Anemia Treatment Market, By Sales Channel
- Hospital Pharmacies
- Dialysis Centers
- Retail Pharmacy Chains
- Mail Order Pharmacies
Global Dialysis Induced Anemia Treatment Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?